Enliven Therapeutics Q3 net loss narrows

Enliven Therapeutics

12/11/2025 21:25

Overview

Enliven reports Q3 net loss of $20.1 mln, down from $23.2 mln last year

Company maintains strong cash position with $478 mln

Completed Phase 1b of ENABLE trial, plans Phase 3 trial in 2026

Outlook

Company plans to initiate Phase 3 trial of ELVN-001 in 2026

Enliven expects cash runway to extend into first half of 2029

Result Drivers

RESEARCH AND DEVELOPMENT EXPENSES: R&D expenses were $18.2 million for the third quarter of 2025, compared to $21.3 million for the third quarter of 2024.

GENERAL AND ADMINISTRATIVE EXPENSES: G&A expenses were $6.9 million for the third quarter of 2025, compared to $5.8 million for the third quarter of 2024.

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$20.15 mln
Q3 Basic EPS
-$0.32
Q3 Income From Operations
-$25.10 mln
Q3 Operating Expenses
$25.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Enliven Therapeutics Inc is $38.00, about 48.3% above its November 11 closing price of $19.64

Press Release: ID:nPn61myXKa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)